Puma Biotechnology (PBYI) Competitors $3.15 +0.02 (+0.64%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.21 +0.06 (+1.87%) As of 03/27/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. AVBP, ORGO, CVAC, GHRS, NUVB, CRMD, IMNM, ABUS, BCYC, and DNTHShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. ArriVent BioPharma Organogenesis CureVac GH Research Nuvation Bio CorMedix Immunome Arbutus Biopharma Bicycle Therapeutics Dianthus Therapeutics ArriVent BioPharma (NASDAQ:AVBP) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Do analysts recommend AVBP or PBYI? ArriVent BioPharma currently has a consensus price target of $39.00, suggesting a potential upside of 110.02%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 122.22%. Given Puma Biotechnology's higher possible upside, analysts clearly believe Puma Biotechnology is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AVBP or PBYI? In the previous week, ArriVent BioPharma had 13 more articles in the media than Puma Biotechnology. MarketBeat recorded 16 mentions for ArriVent BioPharma and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.37 beat ArriVent BioPharma's score of 0.88 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in AVBP or PBYI? Puma Biotechnology received 533 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 67.23% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesPuma BiotechnologyOutperform Votes55467.23% Underperform Votes27032.77% Is AVBP or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to ArriVent BioPharma's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Puma Biotechnology 9.56%41.60%10.71% Do institutionals and insiders believe in AVBP or PBYI? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, AVBP or PBYI? Puma Biotechnology has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-7.23Puma Biotechnology$230.47M0.68$21.59M$0.615.16 Which has more volatility & risk, AVBP or PBYI? ArriVent BioPharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Puma Biotechnology has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. SummaryPuma Biotechnology beats ArriVent BioPharma on 13 of the 18 factors compared between the two stocks. Remove Ads Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$156.28M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio6.567.2023.1619.03Price / Sales0.68226.01386.8193.17Price / Cash4.1965.6738.1634.64Price / Book2.816.476.914.33Net Income$21.59M$141.90M$3.20B$247.06M7 Day Performance-10.26%-3.20%-2.30%-0.37%1 Month Performance-12.01%-5.64%2.86%-3.85%1 Year Performance-40.57%-7.47%10.51%1.27% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology4.4494 of 5 stars$3.15+0.6%$7.00+122.2%-43.5%$156.28M$230.47M6.56200Positive NewsAVBPArriVent BioPharma1.4346 of 5 stars$20.21+3.5%$39.00+93.0%+3.2%$687.46MN/A-7.8640ORGOOrganogenesis3.5813 of 5 stars$5.42+11.1%$5.50+1.5%+69.2%$687.41M$482.04M-90.33950CVACCureVac3.9857 of 5 stars$3.00+3.8%$10.00+233.3%-8.2%$671.64M$543.28M5.45880News CoverageGHRSGH Research2.5021 of 5 stars$12.88+3.0%$30.86+139.6%+14.4%$670.12MN/A-16.3010NUVBNuvation Bio2.0445 of 5 stars$1.96+3.4%$8.33+326.3%-52.7%$662.12M$7.87M-0.9060Analyst ForecastCRMDCorMedix2.6232 of 5 stars$10.77-1.3%$16.00+48.6%+61.3%$653.49M$12.26M-13.3030Earnings ReportAnalyst ForecastOptions VolumeNews CoverageIMNMImmunome1.9533 of 5 stars$8.15-0.4%$25.50+212.9%-71.5%$650.18M$10.13M-1.0040Insider TradeNews CoverageGap UpABUSArbutus Biopharma1.4613 of 5 stars$3.39+3.4%$5.50+62.2%+25.8%$642.38M$6.74M-7.8890Earnings ReportAnalyst RevisionNews CoverageBCYCBicycle Therapeutics1.9498 of 5 stars$9.20+1.3%$29.14+216.8%-62.6%$636.66M$35.28M-2.80240High Trading VolumeDNTHDianthus Therapeutics1.3915 of 5 stars$19.41-0.4%$54.33+179.9%-35.1%$623.55M$6.24M-7.7680 Remove Ads Related Companies and Tools Related Companies ArriVent BioPharma Competitors Organogenesis Competitors CureVac Competitors GH Research Competitors Nuvation Bio Competitors CorMedix Competitors Immunome Competitors Arbutus Biopharma Competitors Bicycle Therapeutics Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBYI Stock Free PBYI Stock Alerts